Clinical trials demonstrated safety of AstraZeneca and Sputnik Light vaccines combination

Monitoring results demonstrated a good safety profile of the combination. No serious adverse events related to vaccination were registered

Lannett receives USFDA safety review for biosimilar insulin glargine

Go-ahead for pivotal clinical trial which is expected to commence by March

Covaxin well tolerated with no safety concerns: Lancet

Covaxin is the only Covid-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the Delta variant at 65.2%

Lancet endorses Sputnik Light for safety and immune response

Sputnik Light has been authorised in more than 15 countries with the registration process ongoing in a further 30 countries

Roche’s 8-year safety data of Ocrevus shows reduced risk in multiple sclerosis patients

New safety data show a consistent benefit-risk profile across all Ocrevus clinical trials

ABB’s ACS360 Drives enhance safety and energy efficiency at Bharat Biotech’s Covaxin plant

ABB Drives play a key role in the cleanroom infrastructure of Bharat Biotech, India’s first indigenous Covid-19 vaccine manufacturer. The drives are easy to commission, use and ensure higher energy efficiency

Real world data from Paraguay shows one-shot Sputnik Light vaccine has high safety and efficacy of 93.5 %

Sputnik Light is the first component (recombinant human adenovirus serotype number 26 (rAd26)) of Sputnik

Piramal Pharma Solutions boosts formulation development at Morpeth site with Korsch XM-12

Ascletis reports positive phase Ib results for oral GLP-1R agonist ASC30 at EASD 2025

The Phase Ib MAD study is a randomized, double-blind, placebo-controlled trial conducted in the United States

AllRock Bio raises $50 million to drive therapy for pulmonary hypertension into phase 2 trials

Funding supports development of first-in-class pan-ROCK inhibitor ROC-101 through Phase 2a clinical testing